SGPSpyGlass Pharma, Inc.
$24.70
$24.70
$17.5652 weeks$29.68
SGP in its own filings
Nothing in SGP's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
17
Events found in the filings · across 91 filings · the record starts in 2025
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 1, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 1, 2025
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 5, 2026
- SEC comment-letter activity7 occurrences
- 2026-01-29
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Santen Holdings US, Inc., a California corporation (“Seller”), and Santen Pharmaceutical Co., Ltd., a Japanese Company (“Parent”)Regulation FD disclosure · Form 8-K
- Aug 6, 2026SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- May 14, 2026SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- Mar 26, 2026SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update.Earnings release · press release
- Mar 9, 2026On March 9, 2026, SpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial.Other event · Form 8-K
- Feb 13, 2026On January 16, 2026, SpyGlass Pharma, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292779) with the Securities and Exchange Commission (as amended, the “Registration Statement”)Director or officer change · Form 8-K
- Feb 9, 2026Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. (the “Company”) on February 5, 2026 in connection with the Company’s initial public offering (the “IPO”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry